Concepts in Development

Concepts in Development

ALTG 16/007 ALKTERNATE:

Single arm phase 2 trial in ALK-rearranged NSCLC alTERNATing lortatinib with crizotinib after progression on first line crizotinib – N Pavlakis

  • This study aims to identify whether a fixed, ongoing alternating schedule of lorlatinib with crizotinib results in ongoing disease control and suppression of detectable innate or acquired ALK gene resistance mutations in blood; and to determine if ALK gene resistance mutations in circulating tumour DNA can be used to identify participants developing resistance before progression is clinically evident
  • Planned recruitment 40 patients from 15 sites
  • Concept submitted and under review for funding
ALTG 16/009 ILLUMINATE:

A Phase 2 study of durvalumab plus tremelimumab in patients with relapsed EGFR mutant NSCLC – C Lee

  • This study aims to evaluate the efficacy and tolerability of combination durvalumab plus tremelimumab in patients with relapsed EGFR mutant NSCLC
  • Planned recruitment 50 from 15 sites
  • Concept submitted and under review for funding
ALTG 16/010 LungCare:

A multicentre randomised controlled trial comparing primary care vs hospital-based follow-up following surgical lobectomy for NSCLC – F Brims

  • Grant application submitted March 2017 to NHMRC, Cancer Australia and Cancer Council
ALTG 17/001 Active surveillance in patients with MPM:

A prospective single arm phase II trial – A Nowak

  • Project grant submission planned for 2018
  • If successful, anticipated study start late 2018